JP2015517484A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517484A5
JP2015517484A5 JP2015510875A JP2015510875A JP2015517484A5 JP 2015517484 A5 JP2015517484 A5 JP 2015517484A5 JP 2015510875 A JP2015510875 A JP 2015510875A JP 2015510875 A JP2015510875 A JP 2015510875A JP 2015517484 A5 JP2015517484 A5 JP 2015517484A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
sequence
peptide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015510875A
Other languages
English (en)
Japanese (ja)
Other versions
JP5982562B2 (ja
JP2015517484A (ja
Filing date
Publication date
Priority claimed from GB201208293A external-priority patent/GB201208293D0/en
Application filed filed Critical
Publication of JP2015517484A publication Critical patent/JP2015517484A/ja
Publication of JP2015517484A5 publication Critical patent/JP2015517484A5/ja
Application granted granted Critical
Publication of JP5982562B2 publication Critical patent/JP5982562B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015510875A 2012-05-11 2013-05-09 ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途 Expired - Fee Related JP5982562B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201208293A GB201208293D0 (en) 2012-05-11 2012-05-11 Hydrochlorice salt of peptide
GB1208293.9 2012-05-11
PCT/GB2013/051201 WO2013167897A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Publications (3)

Publication Number Publication Date
JP2015517484A JP2015517484A (ja) 2015-06-22
JP2015517484A5 true JP2015517484A5 (enExample) 2016-06-30
JP5982562B2 JP5982562B2 (ja) 2016-08-31

Family

ID=46396890

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015510875A Expired - Fee Related JP5982562B2 (ja) 2012-05-11 2013-05-09 ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途

Country Status (17)

Country Link
US (1) US9657061B2 (enExample)
EP (1) EP2847209B8 (enExample)
JP (1) JP5982562B2 (enExample)
KR (1) KR20150014955A (enExample)
CN (1) CN104428311B (enExample)
AU (1) AU2013257784A1 (enExample)
BR (1) BR112014028130A2 (enExample)
CA (1) CA2873120A1 (enExample)
EA (1) EA201492068A1 (enExample)
GB (2) GB201208293D0 (enExample)
HK (1) HK1201850A1 (enExample)
IL (1) IL235388A (enExample)
IN (1) IN2014DN09367A (enExample)
MX (1) MX2014013394A (enExample)
SG (1) SG11201407446TA (enExample)
WO (1) WO2013167897A1 (enExample)
ZA (1) ZA201408290B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
KR102435015B1 (ko) 2014-12-23 2022-08-22 이매틱스 바이오테크놀로지스 게엠베하 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES2986555T3 (es) 2015-03-27 2024-11-11 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores (SEQ ID 243 – SPC25-001)
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
EP4021920A4 (en) * 2019-08-26 2023-08-16 Auro Peptides LTD IMPROVED PROCESS FOR PRODUCTION OF ETELCALCETIDE HYDROCHLORIDE
TWI792442B (zh) * 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453539B1 (en) * 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
SI2083856T1 (sl) * 2007-08-15 2011-02-28 Circassia Ltd Peptidi za desenzibilizacijo proti alergijam
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
ES2617921T3 (es) * 2010-03-31 2017-06-20 Stabilitech Ltd. Excipientes para estabilizar partículas virales

Similar Documents

Publication Publication Date Title
JP2015517484A5 (enExample)
NZ759512A (en) Delayed release compositions of linaclotide
PE20241305A1 (es) Analogos de amilina
PH12018550201A1 (en) Hepatitis b antiviral agents
JP2015078230A5 (enExample)
PH12018502465A1 (en) Mic-1 compounds and use thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
EA201391018A1 (ru) Препараты иммуносупрессантов
WO2015114395A9 (en) Process for the preparation of vortioxetine salts
PH12018501236A1 (en) Pharmaceutical composition comprising a potent inhibitor urat1
JP2015513318A5 (enExample)
CA3027148C (en) Formulation for administration of rna
MX2021006969A (es) Ligante peptidico.
JP2020513418A5 (enExample)
TW201613557A (en) Stable aqueous recombinant protein formulations
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
WO2013021284A3 (en) Anti-il-6 vaccine composition
JP2018529626A5 (enExample)
WO2015024022A3 (en) Designed peptides for tight junction barrier modulation
WO2012162637A3 (en) Vaccine adjuvants from self-assembling peptides
JP2016160183A5 (ja) 筋萎縮抑制剤及び筋萎縮抑制用飲食品
MY189021A (en) Peptides and uses therefor as antiviral agents
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX2013003551A (es) Formas en estado solido de un potente inhibidor del vch.